---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-041204"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2025-04-29T23:59:59+00:00"
generated_at: "2026-05-23T03:54:21.227966+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Entrada Therapeutics restructures, reduces workforce 20% to focus on Duchenne MD candidates

## Summary
- Board approved strategic plan on April 29, 2025; workforce reduction of approximately 20% effective May 2.
- Estimated $2 million in total charges (severance, healthcare) primarily in Q2 2025.
- Company prioritizing DMD candidates ENTR-601-44, -45, -50, -51 and ocular programs.
- Anticipates cost savings to extend cash runway into Q2 2027.
- Workforce reduction substantially completed by end of Q2 2025.

## SEC filing metadata
- accession: 0001104659-25-041204
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2025-04-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000110465925041204/0001104659-25-041204-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000110465925041204/tm2513421d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-041204
- JSON: https://secwatch.observer/filing/0001104659-25-041204.json
- Plain text: https://secwatch.observer/filing/0001104659-25-041204.txt

## Key facts
- Restructurings & Charges
  Entrada Therapeutics, Inc. announced a restructuring with charges of approximately $2 million affecting research areas (approximately 20%).
  - Type: restructuring
  - Charge: approximately $2 million
  - Affected area: research areas
  - Headcount: approximately 20%
  source text: -45, -50, and -51), ocular programs and maturing platform investments. In connection with the new strategic plan, the Company expects to incur aggregate charges of approximately $2 million in total expenses related to the reduction in force, consisting primarily of one-time severance payments and continued healthcare benefits for a specific period of time. The
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689375/000110465925041204/0001104659-25-041204-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.